Anti-SLAMF7 monoclonal antibody (specialist)

Elotuzumab

Brand names: Empliciti

Elotuzumab is a monoclonal antibody used in combination with other agents to treat relapsed or refractory multiple myeloma.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

It targets SLAMF7 (CS1), a glycoprotein expressed on myeloma and natural killer cells, directly activating natural killer cells and promoting antibody-dependent cellular cytotoxicity against myeloma cells.

Prescribing in practice

Infusion-related reactions are common, so premedication is given and the infusion rate is managed carefully under supervision.
It is always used in combination with other antimyeloma agents rather than as monotherapy.
There is an increased risk of infection, and it may interfere with serum protein electrophoresis used to monitor myeloma response.

Monitoring

Monitor for infusion reactions, infections and full blood count, and be aware of interference with myeloma response assays during treatment.

Counselling the patient

Premedication will be given before each infusion to lower the chance of a reaction.
Report fever or other signs of infection promptly.

Evidence & guidelines

Elotuzumab combination therapy is supported by trial evidence (the ELOQUENT studies) in relapsed or refractory multiple myeloma.

Reference: NICE TA505; BSH myeloma guidelines; ESMO; SmPC; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Curated clinical cross-links plus same-class fallbacks.

Calculators

Pathways